Embecta (EMBC) vs Neuropace (NPCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuropace (NPCE) has outperformed Embecta (EMBC) over the past year, losing 44.6% versus a loss of 58.7%. Embecta is the larger company by market cap ($341.1 million vs $273.9 million), about 1.2 times the size, while Neuropace is growing revenue faster (+25.1% vs -3.8%). Embecta pays a dividend yielding 7.64%, while Neuropace does not currently pay one.
Embecta converts more of its revenue into profit, with a net margin of 8.8% versus -21.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | NPCE |
|---|---|---|
| Share price | $6.02 | $7.95 |
| Market cap | $341.09M | $273.89M |
| 1-day change | -2.75% | -2.33% |
| YTD return | -49.33% | -48.51% |
| 1-year return | -58.68% | -44.60% |
| 5-year return | — | -32.80% |
| P/E ratio (TTM) | 4.10 | — |
| Forward P/E | 3.42 | — |
| EPS (TTM) | $1.47 | $-0.56 |
| Dividend yield | 7.64% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| Revenue (latest FY) | $1.08B | $99.99M |
| Revenue growth (YoY) | -3.80% | +25.13% |
| Net income (latest FY) | $95.40M | $-21.46M |
| Gross margin | 62.64% | 77.23% |
| Operating margin | 22.41% | -16.34% |
| Net margin | 8.83% | -21.47% |
| 52-week high | $14.78 | $19.60 |
| 52-week low | $2.77 | $5.46 |
| Distance from 52-week high | -59.27% | -59.44% |
| Analyst consensus | none | buy |
| Avg. price target upside | -33.55% | +53.71% |
| Average volume | 1.01M | 270.76K |
| Shares outstanding | 56.66M | 34.45M |
| Employees | 1,850 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NPCE has outperformed EMBC by 14.1 percentage points over the past year.
- Embecta offers a meaningfully higher dividend yield (7.64% vs 0.00%).
- Embecta is more profitable, keeping 8.8 cents of every revenue dollar as net income versus -21.5 cents for Neuropace.
- Neuropace grew revenue faster in its latest fiscal year (+25.13% vs -3.80%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 216 employees
EMBC vs NPCE FAQ
Which is bigger, Embecta or Neuropace?
Embecta (EMBC) is larger, with a market capitalization of $341.09M compared with $273.89M for Neuropace (NPCE).
Which stock has performed better over the past year, EMBC or NPCE?
NPCE returned -44.60% over the past 12 months, compared with -58.68% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Embecta or Neuropace?
Embecta pays a dividend yielding 7.64%, while Neuropace does not currently pay a regular dividend.
Are Embecta and Neuropace in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.